State-based influenza vaccine programs announced in Qld and WA
Queensland and Western Australia have each announced free influenza vaccine programs for 2024.
In Queensland, all residents aged 6 months and older can access the influenza vaccine for free in 2024. The program will conclude on 30 September 2024.
In Western Australia, free influenza vaccines will be available for people aged 6 months and older during the months of May and June.
Influenza vaccination is funded through the National Immunisation Program (NIP) across Australia for:
- trẻ em từ 6 tháng đến < 5 tuổi
- all adults aged 65 years and older
- specific populations aged 5 to 64 years who are greater risk of devleoping complications from influenza.
Queensland Health: 2024 Free flu vaccination program
Government of Western Australia: Free flu jabs available throughout May and June 2024
MVEC: Cúm
Victorian Department of Health: Nurse immunisers, pharmacist immunisers and ATSIHP immunisers approved to administer Arexvy
In Victoria, nurse immunisers, pharmacist immunisers and Aboriginal and Torres Strait Islander health practitioner (ATSIHP) immunisers are authorised to administer the respiratory syncytial virus (RSV) vaccine Arexvy.
RSV is a virus that causes both upper and lower respiratory tract infections. Arexvy is used to prevent RSV in people aged 60 years and older, and is recommended for:
- All adults aged 75 years and older
- First Nations adults aged 60 years and older
- adults aged 60 to 74 years with certain medical conditions.
Read more about Arexvy and RSV on our RSV reference page.
Q fever records now to be added to AIR
From 15 April 2024, immunisation providers can report Q fever vaccines (Q-Vax) and natural immunity information to the Australian Immunisation Register (AIR).
Các Australian Q Fever Register will be closed. Those with an existing Q fever record can access their Q fever vaccination/natural immunity eStatement via the Australian Q Fever Register and take it to an immunisation provider to be reported to AIR.
Individuals can access the Australian Q Fever Register, including their Q Fever eStatement, until 30 June 2025.
TGA: Abrysvo RSV vaccine registered for use
On 20 March 2024, the respiratory syncytial virus (RSV) vaccine Abrysvo was registered by the Therapeutic Goods Administration (TGA). Abrysvo is indicated for:
- pregnant people between 24 and 36 weeks gestation for the prevention of lower respiratory tract disease caused by RSV in infants from birth to 6 months of age
- adults aged 60 years and older for the prevention of lower repiratory tract disease caused by RSV.
Abrysvo is a recombinant respiratory syncytial virus pre-fusion F protein vaccine. Guidance on its use is yet to come.
TGA: Guidance and resources on Abrysvo
MVEC: RSV
ABC: Q fever case spike in Qld drives push for more accessible vaccine
As reported by ABC in March, Queensland has reported 89 Q fever infections since the beginning of 2024, an increase of almost 90% compared to the same time in 2023.
Q fever is caused by infection with the Coxiella burnetii bacteria. Bacterial reservoirs for human infection primarily include cattle, sheep, and goats; however, other animals can also be infected. Transmission occurs via the inhalation of infected aerosols or contaminated soil, dusts or water droplets.
The vaccine Q-Vax is recommended for those aged over 15 years in specific high-risk occupational groups. Q-Vax is available for private purchase. Researchers in Queensland are developing a new vaccine which they hope will be more accessible.
ABC: Q fever case spike in Qld drives renewed push for more accessible vaccine for ‘nasty’ bacterial disease (March 2024)
ABC: Q fever vaccine funding boosted as the hunt for a better solution continues (August 2020)
MVEC: Q fever
RSV programs announced in NSW and Qld
New South Wales and Queensland have both announced respiratory syncytial virus (RSV) programs to provide protection for infants and children.
In New South Wales, infants vulnerable to severe illness from RSV will be eligible to receive nirsevimab, a monoclonal antibody (available in Australia under the brand name Beyfortus). This includes:
- babies born before 37 weeks gestation and adter 31 October 2023
- Aboriginal and Torres Strait Islander babies born after 31 October 2023
- other infants living with specific chronic and complex health conditions.
Read more on the NSW Health website.
The Queensland program will also provide nirsevimab (brand name, Beyfortus) to eligible infants and young children, including:
- all newborn infants from birth
- Aboriginal and Torres Strait Islander infants up to < 8 months of age
- infants with certain complex medical conditions up to < 8 months of age
- young children with certain complex medical conditions from 8–19 months of age (until 31 October 2024).
For more details, read about the new program on the Queensland Health website.
AusVaxSafety Summary report 2022 published
Since 2014, AusVaxSafety has monitored the safety of all vaccines on the National Immunisation Program (NIP) and all COVID-19 vaccines used in Australia.
Surveillance is undertaken via a short vaccine safety survey which is sent to people (or their carers) who received their vaccine at a participating AusVaxSafety site across Australia. The surveys give participants the opportunity to report any adverse events following immunisation that they experienced and if they sought medical attention for any reason.
The Vaccine safety in Australia AusVaxSafety Summary report 2022 is now available on the Department of Health and Aged Care website.
NCIRS: New influenza resource
Các Trung tâm Nghiên cứu và Giám sát Tiêm chủng Quốc gia (NCIRS) has recently published a new Influenza reference page which includes influenza fact sheets and FAQs, vaccine coverage and safety data, and clinical/community resources.
NCRIS: Influenza immunisation
MVEC: Cúm
Western Australia announces funding for RSV protection
Western Australia has announced that they will roll out a statewide program for long-acting monoclonal antibody Nirsevimab from April 2024. Nirsevimab (available in Australia under the brand name Beyfortus) is indicated for the prevention of respiratory syncytial virus (RSV) disease in neonates and infants.
Western Australian children eligible for Nirsevimab include:
- all infants from birth to under 8 months
- infants from 8 months to 19 months at increased risk of severe RSV.
Nirsevimab will be available at birthing hospitals, GP practices, community health clinics and at Aboriginal Medical Services across Western Australia.
There were approximately 128,000 confirmed RSV cases in Australia in 2023, including approximately 65,000 children aged 4 years and under.
For more information, see MVEC: RSV Và WA Media Statement on RSV
ATAGI: Statement on the administration of seasonal influenza vaccines in 2024
ATAGI (Australian Technical Advisory Group on Immunisation) has published their recommendations for the use seasonal influenza vaccines in Australia in 2024.
Influenza vaccines are recommended annually and are funded on the National Immunisation Program (NIP) for:
- children aged 6 months to less than 5 years
- all adults aged 65 years and older
- specific populations aged 5 to 64 years who are at greatest risk of developing complications from influenza infection (including phụ nữ có thai, Người bản địa, and those with certain medical risk factors).
For more information refer to: ATAGI: Statement on the administration of seasonal influenza vaccines in 2024